Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will soon enter large-scale, phase 3, placebo-controlled randomized clinical trials. To facilitate harmonized evaluation and com...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Intern Med
Päätekijät: Mehrotra, Devan V., Janes, Holly E., Fleming, Thomas R., Annunziato, Paula W., Neuzil, Kathleen M., Carpp, Lindsay N., Benkeser, David, Brown, Elizabeth R., Carone, Marco, Cho, Iksung, Donnell, Deborah, Fay, Michael P., Fong, Youyi, Han, Shu, Hirsch, Ian, Huang, Ying, Huang, Yunda, Hyrien, Ollivier, Juraska, Michal, Luedtke, Alex, Nason, Martha, Vandebosch, An, Zhou, Honghong, Cohen, Myron S., Corey, Lawrence, Hartzel, Jonathan, Follmann, Dean, Gilbert, Peter B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American College of Physicians 2020
Aiheet:
Research and Reporting Methods
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596738/
https://ncbi.nlm.nih.gov/pubmed/33090877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/M20-6169
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia